Key result
HSP90 inhibitors reduced intracellular Hepatitis C virus Core protein levels and restored growth in budding yeast by targeting the Hsc82-dependent stability of the nascent Core polypeptide.
The yeast system can be utilized to select compounds that target the C-terminal region of the HCV Core protein to reduce its stability.
Answers are grounded in this paper and cite their sources.
HSP90 inhibitors lack clinical support in HCV; leaves open yeast models for screening Core-targeted compounds.
Hepatitis C virus core protein (Core) contributes to HCV pathogenicity. Here, we demonstrate that Core impairs growth in budding yeast. We identify HSP90 inhibitors as compounds that reduce intracellular Core protein level and restore yeast growth. Our results suggest that HSC90 (Hsc82) may function in the protection of the nascent Core polypeptide against degradation in yeast and the C-terminal region of Core corresponding to the organelle-interaction domain was responsible for Hsc82-dependent stability. The yeast system may be utilized to select compounds that can direct the C-terminal region to reduce the stability of Core protein.
No takes yet. Share an insight, caveat, or question.
Kubota et al. (2012) studied Hepatitis C virus core protein pathogenicity. HSP90 inhibitors was evaluated on Intracellular Core protein level and yeast growth. HSP90 inhibitors reduced intracellular Hepatitis C virus Core protein levels and restored growth in budding yeast by targeting the Hsc82-dependent stability of the nascent Core polypeptide.
Synapse has enriched 10 related papers. Consider them for comparative context: